Skip to main content
SpringerLink
Log in

Atopische Dermatitis: Therapieoption Dupilumab

  • Literatur kompakt
  • Published:
Allergo Journal Aims and scope Submit manuscript

Der monoklonale Antikörper Dupilumab hat sich gegen mäßig bis schwer ausgeprägte atopische Dermatitis (AD) bewährt. Die behandelten Patienten hatten zuvor nicht auf Glukokortikoide und Calcineurin-Inhibitoren angesprochen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Beck LA et al. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. N Engl J Med 2014; 371: 130–9

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Robert Bublak

Authors
  1. Robert Bublak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bublak, R. Atopische Dermatitis: Therapieoption Dupilumab. Allergo J 23, 12 (2014). https://doi.org/10.1007/s15007-014-0677-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15007-014-0677-7

Search

Navigation